MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm.
MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm.
复制标题
MTA1 表达可以对≤3 cm 多灶性非小细胞肺癌患者的风险进行分层
DOI：
10.2147/tcrm.s331317
复制
发表时间：
2021
影响因子：
2.8
通讯作者：
Ye L
中科院分区：
文献类型：
--
作者：
Wang W;Hu Z;Ma M;Yin H;Huang Y;Zhao G;Cui X;Sun Q;Yang Y;Yang Y;Wang B;Ye L
目前，对于≤3 cm的多灶性非小细胞肺癌（NSCLC）患者的术后辅助化疗尚无统一的指导标准。因此，迫切需要探索预后分子标志物来识别多灶性NSCLC ≤3 cm的高危患者。我们的目的是探索转移相关蛋白1（MTA 1）表达在多灶性非小细胞肺癌（≤3 cm）患者风险分层中的潜在价值。我们回顾性分析了≤3 cm的多灶性NSCLC患者的临床资料和术后生存资料。石蜡包埋的组织切片用于免疫组织化学。采用半定量免疫反应性评分（IRS）系统评价MTA 1的核表达。采用SPSS 23.0统计软件对数据进行分析。119例患者的259个病灶中MTA 1核表达的IRS范围为2.2至11.7（中位数：5.6）。我们的研究结果表明，MTA 1的表达是最高的肺腺癌的高危病理亚型。多原发肺癌（MPLCs）中MTA 1的表达低于肺内转移癌（IPMs）。中位随访时间为25.97个月。MPLC患者的无病生存期（DFS）明显优于IPM患者，而MTA 1高表达患者的DFS明显低于MTA 1低表达患者。多变量考克斯分析显示，在多灶性NSCLC ≤3 cm患者中，MTA 1高表达（风险比：7.937，95%置信区间：2.433-25.64，p =0.001）是DFS恶化的统计学显著预测因素。MTA 1表达可对多灶性NSCLC ≤3 cm患者的风险进行分层。MTA 1免疫组化评分>5.6的患者术后复发风险高，这些患者可能从术后辅助化疗中获益。
Currently, there is no uniform standard to guide postoperative adjuvant chemotherapy for patients with multifocal non-small cell lung cancers (NSCLCs) ≤3 cm. Therefore, there is an urgent need to explore prognostic molecular markers to identify high-risk patients with multifocal NSCLCs ≤3 cm. We aimed to explore the potential value of metastasis-associated protein 1(MTA1) expression in risk stratification of patients with multifocal NSCLCs ≤3 cm. We retrospectively analyzed the clinical data and postoperative survival data of patients with multifocal NSCLCs ≤3 cm. Paraffin-embedded tissue sections were used for immunohistochemistry. Semiquantitative immunoreactivity scoring (IRS) system was used to evaluate the nuclear expression of MTA1. SPSS software (version 23.0) was used to analyze the data. The IRS of MTA1 nuclear expression in 259 lesions of 119 patients ranged from 2.2 to 11.7 (median: 5.6). Our results showed that MTA1 expression was highest in high-risk pathological subtypes of lung adenocarcinoma. MTA1 expression in multiple primary lung cancers (MPLCs) was lower than that in intrapulmonary metastases (IPMs). The median follow-up duration was 25.97 months. The disease-free survival (DFS) of patients with MPLCs was significantly better than that of patients with IPMs, and the DFS of patients with high MTA1 expression was significantly worse than that of patients with low MTA1 expression. Multivariate Cox analysis showed that high MTA1 expression (hazard ratio: 7.937, 95% confidence interval: 2.433–25.64, p =0.001) was a statistically significant predictor of worse DFS in patients with multifocal NSCLCs ≤3 cm. MTA1 expression can stratify the risk in patients with multifocal NSCLCs ≤3 cm. Patients with MTA1 immunohistochemical score >5.6 are at a high risk of postoperative recurrence, and these patients may benefit from postoperative adjuvant chemotherapy.